Stem-cell memory T (TSCM) cells are able to self-renew, persist long term, and mount potent anti-tumor responses. These properties make them attractive for next-generation CAR T-cell therapies. However, their clinical potential has not previously been demonstrated in humans. A team of researchers co-led by Professor Luca Gattinoni from the Leibniz Institute for Immunotherapy (LIT) and Dr. James Kochenderfer from the National Cancer Institute has published a new study in Cell reporting, for the first time, that CAR T cells designed to acquire a TSCM phenotype demonstrate a favorable safety profile and can induce complete remissions at remarkably low doses without…